Abstract

PHARMACOLOGICAL PROFILE OF EMPAGLIFLOZIN: MECHANISM OF ACTION AND THERAPEUTIC APPLICATIONS

Ujjwal Maan*, Komal Dagar and Hencie Maan

.

Abstract

The prevalence of diabetes mellitus rose in 2014, partly due to the release of new treatments. Empagliflozin, a very successful therapy for type 2 diabetes mellitus, was granted FDA clearance in 2014. The objective of this study is to assess the suitable commencement, contraindications, and adverse effects of empagliflozin. Empagliflozin can be provided either as a monotherapy or in conjunction with metformin and other drugs, such as linagliptin. Although the price is expensive, these combinations are recommended to decrease mortality and control blood glucose levels when lifestyle changes and metformin alone are not enough. In 2016, the FDA granted approval for the use of empagliflozin in lowering the risk of cardiovascular death among individuals diagnosed with type 2 diabetes. This study will examine the indications, administration, side effects, and monitoring necessary for empagliflozin medication, highlighting the need of interprofessional teamwork in maximising patient outcomes.

Keywords: .